Catalyst Pharmaceuticals Inc. (CPRX)
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
Call End: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Samantha Semenkow - Citibank Jason Gerberry - Bank of America Leland Gershall - Oppenheimer & Company Joe Catanzaro - Piper Sandler Operator Greetings, and welcome to the Catalyst Pharmaceuticals' Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.33 per share a year ago.
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
